{"id":2615,"company":{"country":"US","currency":"USD","exchange":"NASDAQ NMS - GLOBAL MARKET","ipo":"2015-07-02","marketCap":7942.0263671875,"name":"Natera Inc","phone":"16502499090","outstanding":120.1500015258789,"symbol":"NTRA","website":"https://www.natera.com/","industry":"Biotechnology"},"price":65.6625,"year":2024,"month":1,"day":10,"weekday":"Wednesday","title":"Impact of government policies on Natera Inc stock market behavior","date":"2024-01-10","url":"/posts/2024/01/10/NTRA","content":[{"section":"Tax Increase:","text":"If the government implements tax increases, it could negatively affect Natera Inc stock market behavior. Higher taxes could reduce disposable income for investors and potentially lead to a decrease in demand for the company's stock. Investors may also seek alternative investment options with lower tax liabilities."},{"section":"Tax Decrease:","text":"A government policy of tax decreases can have a positive impact on Natera Inc stock market behavior. Lower taxes can increase investors' disposable income, potentially leading to higher demand for the company's stock. The company's financial performance may improve as consumers have more spending power due to lower tax burdens."},{"section":"Tax Incentives for Healthcare Companies:","text":"If the government introduces tax incentives specifically targeted at healthcare companies like Natera Inc, it could positively impact the company's stock market behavior. Such incentives might encourage investment in the company and attract more capital, leading to an increase in the stock's value. This policy could also boost confidence in Natera Inc's future growth prospects."},{"section":"Tax Reforms Benefitting the Biotechnology Sector:","text":"Government tax reforms focusing on the biotechnology sector as a whole, including Natera Inc, can have a significant impact on stock market behavior. The enactment of favorable tax policies could lead to increased investment in biotech companies and potentially boost Natera Inc's stock price. These reforms might foster innovation, research, and development in the sector, further enhancing the company's value."},{"section":"Tax Changes Affecting Research and Development Deductions:","text":"If government policies reduce tax benefits or deductions related to research and development (R\u0026D) expenses, the stock market behavior of Natera Inc might be negatively affected. Natera relies on R\u0026D investments to develop innovative products and stay competitive in the market. Any reduction in R\u0026D tax benefits could hinder the company's ability to invest in research activities and potentially impact its long-term growth prospects, influencing stock prices."},{"section":"Regulatory Environment Changes:","text":"Changes in the regulatory environment can also affect Natera Inc stock market behavior. Government policies related to healthcare regulations, licensing, or approvals can impact the company's operations and market opportunities. Investors closely monitor regulatory changes as they can either strengthen or weaken the company's position, subsequently influencing stock prices."}],"tags":["LongSignals","Long","Biotechnology"],"news":[{"category":"company","date":1704801600,"headline":"Natera Announces Preliminary Fourth Quarter and Full Year 2023 Revenues","id":124944540,"image":"https://media.zenfs.com/en/business-wire.com/66af37a0f4b8e9d17c81d15e5d3bd745","symbol":"NTRA","publisher":"Yahoo","summary":"AUSTIN, Texas, January 09, 2024--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing, today announced preliminary revenue results for the fourth quarter and full year ended Dec. 31, 2023. The Company expects the following:","url":"https://finance.yahoo.com/news/natera-announces-preliminary-fourth-quarter-120000091.html"},{"category":"company","date":1704702712,"headline":"Healthcare Outlook 2024","id":124914795,"image":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1156373123/image_1156373123.jpg?io=getty-c-w1536","symbol":"NTRA","publisher":"SeekingAlpha","summary":"The healthcare sector was flat in 2023 year as a result of some unique issues. Check out the healthcare outlook for 2024.","url":"https://seekingalpha.com/article/4661677-healthcare-outlook-2024"},{"category":"company","date":1704602340,"headline":"BTIG Keeps Their Buy Rating on Natera (NTRA)","id":124907866,"image":"","symbol":"NTRA","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3288887397"},{"category":"company","date":1704601200,"headline":"It's JPM time! Which medtechs are expected to issue updates this week?","id":124908719,"image":"","symbol":"NTRA","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3289324995"},{"category":"company","date":1704361800,"headline":"First Week of February 16th Options Trading For Natera (NTRA)","id":124864700,"image":"","symbol":"NTRA","publisher":"Stock Options Channel","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3284611153"},{"category":"company","date":1704184140,"headline":"BTIG Remains a Buy on Natera (NTRA)","id":124815211,"image":"","symbol":"NTRA","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3281157659"},{"category":"company","date":1703930511,"headline":"Insider Sell: CFO Michael Brophy Sells 2,292 Shares of Natera Inc (NTRA)","id":124779133,"image":"https://media.zenfs.com/en/us.finance.gurufocus/618be5c108f8169c08a496cdf9ad3d21","symbol":"NTRA","publisher":"Yahoo","summary":"Michael Brophy, the Chief Financial Officer of Natera Inc (NASDAQ:NTRA), executed a sale of 2,292 shares in the company on December 29, 2023, according to a recent SEC Filing.","url":"https://finance.yahoo.com/news/insider-sell-cfo-michael-brophy-100151534.html"},{"category":"company","date":1703854800,"headline":"Natera to Participate in the 42nd Annual J.P. Morgan Healthcare Conference","id":124768308,"image":"https://media.zenfs.com/en/business-wire.com/bfb0b9c3413fa7b3997bce58e87f05f5","symbol":"NTRA","publisher":"Yahoo","summary":"AUSTIN, Texas, December 29, 2023--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that it will participate in the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Tuesday, Jan. 9, 2024 at 3:45 p.m. PT (6:45 p.m. ET). Members of Natera’s management will deliver a presentation and host a Q\u0026A with the investment community at the conference.","url":"https://finance.yahoo.com/news/natera-participate-42nd-annual-j-130000401.html"},{"category":"company","date":1703844480,"headline":"Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet","id":124766692,"image":"","symbol":"NTRA","publisher":"Benzinga","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3277139845"},{"category":"company","date":1703838060,"headline":"Expedia To Rally Around 10%? Here Are 10 Top Analyst Forecasts For Friday","id":124765406,"image":"","symbol":"NTRA","publisher":"Benzinga","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3277043876"},{"category":"company","date":1703836020,"headline":"Ride-Sharing Stocks Highlight Friday’s Top Wall Street Upgrades and Downgrades","id":124765407,"image":"","symbol":"NTRA","publisher":"247WallSt","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3277015227"},{"category":"company","date":1703834820,"headline":"NeoGenomics price target lowered by $3 at TD Cowen, here's why","id":124766694,"image":"","symbol":"NTRA","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3276997681"},{"category":"company","date":1703829900,"headline":"NeoGenomics price target lowered to $21 from $25 at BTIG","id":124766695,"image":"","symbol":"NTRA","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3276933508"},{"category":"company","date":1703829720,"headline":"Natera price target raised by $10 at BTIG, here's why","id":124766696,"image":"","symbol":"NTRA","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3276931420"},{"category":"company","date":1703829720,"headline":"The Analyst Landscape: 8 Takes On Natera","id":124772547,"image":"","symbol":"NTRA","publisher":"Benzinga","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3276931544"},{"category":"company","date":1703827260,"headline":"Analysts’ Opinions Are Mixed on These Healthcare Stocks: Natera (NTRA) and Co-Diagnostics (CODX)","id":124772549,"image":"","symbol":"NTRA","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3276899612"},{"category":"company","date":1703826480,"headline":"Natera price target raised to $64 from $56 at Goldman Sachs","id":124766699,"image":"","symbol":"NTRA","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3276889591"},{"category":"company","date":1703761260,"headline":"What You Missed On Wall Street This Morning","id":124746161,"image":"","symbol":"NTRA","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3275889104"},{"category":"company","date":1703753460,"headline":"Natera wins court order barring NeoGenomics from selling RaDaR assay (update)","id":124746370,"image":"","symbol":"NTRA","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3275769734"},{"category":"company","date":1703747640,"headline":"NeoGenomics to appeal preliminary injunction by North Carolina court","id":124746373,"image":"","symbol":"NTRA","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3275686106"},{"category":"company","date":1703742540,"headline":"Natera wins court order barring NeoGenomics from selling RaDaR assay","id":124746376,"image":"","symbol":"NTRA","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3275620844"},{"category":"company","date":1703742240,"headline":"Here’s a ‘solid contrarian idea’ for 2024, according to BTIG’s Krinsky","id":124745270,"image":"","symbol":"NTRA","publisher":"MarketWatch","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3275615942"},{"category":"company","date":1703740981,"headline":"CareDx's Turmoil: Risks Appear Priced In","id":124741806,"image":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1028267542/image_1028267542.jpg?io=getty-c-w1536","symbol":"NTRA","publisher":"SeekingAlpha","summary":"CareDx specializes in solutions for transplant patients, but faces challenges, including legal setbacks and regulatory hurdles. Learn why I rate CDNA stock a hold for now.","url":"https://seekingalpha.com/article/4660076-caredx-turmoil-risks-appear-priced-in"},{"category":"company","date":1703738880,"headline":"Natera Wins Preliminary Injunction in Patent Infringement Lawsuit Against NeoGenomics’ RaDaR Test","id":124747608,"image":"https://media.zenfs.com/en/business-wire.com/a5552c1107202a884c2d0884a8dbf9c1","symbol":"NTRA","publisher":"Yahoo","summary":"AUSTIN, Texas, December 28, 2023--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that the federal District Court for the Middle District of North Carolina has issued a preliminary injunction, effective immediately, enjoining the RaDaR assay from NeoGenomics Labs, Inc. (\"NeoGenomics\").","url":"https://finance.yahoo.com/news/natera-wins-preliminary-injunction-patent-044800188.html"},{"category":"company","date":1703737080,"headline":"Natera wins preliminary injunction in NeoGenomics patent infringement lawsuit","id":124746382,"image":"","symbol":"NTRA","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3275554663"},{"category":"company","date":1703733660,"headline":"What You Missed On Wall Street On Thursday","id":124751339,"image":"","symbol":"NTRA","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3276139780"},{"category":"company","date":1703728680,"headline":"NeoGenomics ruling seen having limited impact on estimates, Needham says","id":124758163,"image":"","symbol":"NTRA","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3276057194"},{"category":"company","date":1703717522,"headline":"Natera : Preliminary Injunction Order","id":124738132,"image":"","symbol":"NTRA","publisher":"Finnhub","summary":"IN THE UNITED STATES DISTRICT COURT ...","url":"https://finnhub.io/api/news?id=2d331c2af4881c51af81dcfa0ffdae92a77daf475d5d9fdf13b98f8ef6e3d69a"},{"category":"company","date":1703706936,"headline":"Natera: Squeezing The Last Drop From NIPT Growth Engine","id":124735171,"image":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/91213667/image_91213667.jpg?io=getty-c-w1536","symbol":"NTRA","publisher":"SeekingAlpha","summary":"Natera has a proven track record and established trust in the technology. Click here to read the analysis of NTRA stock and my recommendation.","url":"https://seekingalpha.com/article/4660019-natera-stock-squeezing-last-drop-nipt-growth-engine-buy"}]}